Clinical Pharmacokinetics of Leflunomide

  title={Clinical Pharmacokinetics of Leflunomide},
  author={Blaž Rozman},
  journal={Clinical Pharmacokinetics},
  • B. Rozman
  • Published 2002
  • Medicine, Biology
  • Clinical Pharmacokinetics
AbstractLeflunomide is the first disease-modifying antirheumatic drug to be approved for rheumatoid arthritis in the past 10 years. Orally administered leflunomide is almost completely converted into its active metabolite A77 1726 (hereafter referred to as M1). M1 displays linear pharmacokinetics at the dosages of leflunomide used in clinical practice. It has a long elimination half-life (approximately 2 weeks), reaching a steady state after approximately 20 weeks. M1 is highly bound to plasma… 

Safety evaluation of leflunomide in rheumatoid arthritis

Its clinical use is limited by the historic parallel development of other agents, including methotrexate, which has become the synthetic DMARD of choice and biological DMARDs that have superior efficacy.

Population Pharmacokinetics of the Active Metabolite of Leflunomide in Pediatric Subjects with Polyarticular Course Juvenile Rheumatoid Arthritis

A population pharmacokinetic (PPK) model for the active metabolite (M1) of leflunomide in patients with juvenile rheumatoid arthritis (JRA) and determine appropriate pediatric doses was established.

Leflunomide for Inflammatory Arthritis in End-Stage Renal Disease on Peritoneal Dialysis: A Pharmacokinetic and Pharmacogenetic Study

Dose adjustment for leflunomide does not appear to be required in the context of ESRD requiring peritoneal dialysis, and novel evidence that a small amount of teriflunomid is removed by peritoneAL dialysis is presented.

Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study

Pharmacokinetic data of disease modifying antirheumatic drugs during hemodialysis are limited to sulfasalazine, methotrexate, and cyclosporine. Only respective anecdotal data have been reported on

Leflunomide pharmacokinetics after single oral administration to dogs.

Leflunomide has been used as an adjunctive therapy for dogs refractory to traditional immunosuppressive drugs and to prevent anti-allograft immune responses and all procedures were approved by the NIH Guide for the Care and Use of Laboratory Animals.

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

While teriflunomide is no more effective than a number of other agents that are used in the treatment of MS, it has a favorable side-effect profile and the convenience of once a day oral administration, and is likely to be a popular agent in the Treatment of MS over the next 5 years.

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis

Teriflunomide has shown a favorable safety and efficacy profile in RRMS and is a therapeutic option for a distinct group of adult patients with RRMS.

Individualization of leflunomide dosing in rheumatoid arthritis patients.

Optizing leflunomide treatment to meet the needs of individuals would hence be beneficial in terms of patient outcomes and health care expenditure, and therapeutic drug monitoring (TDM) may be useful.

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

Determination of serum A77 1726 concentrations in patients with insufficient response to treatment may help when decisions have to be made about continuation of treatment or dose adjustment.

Use of a Cholestyramine Washout in a Patient With Septic Shock on Leflunomide Therapy

A case of a patient with severe septic shock secondary to a prosthetic joint infection in which therapeutic levels of leflunomide were discovered, despite the patient ceasing therapy several weeks prior to admission, is reported.



Leflunomide: a review of its use in active rheumatoid arthritis.

Leflunomide is a disease-modifying antirheumatic drug which reduces the signs and symptoms of inflammatory arthritis and delays the radiological progression of disease in adult patients with active rheumatoid arthritis.

Leflunomide and malononitriloamides.

Leflunomide is effective when administered at daily doses of 10 and 25 mg to patients with active rheumatoid arthritis, and improved efficacy at the 25 mg dose is associated with a higher incidence of adverse effects (gastrointestinal symptoms, weight loss, allergic reactions, skin rash, and reversible alopecia).

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

The combination of methotrexate and leflunomide has therapeutic potential in RA and was generally well tolerated clinically, with the exception of elevations of liver enzyme levels.

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Both leflunomide and methotrexate are efficacious for prolonged treatment of RA and this benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis

Improved efficacy at the 25-mg dose was associated with a higher incidence of AEs, and Randomized, placebocontrolled trials using daily doses of 10 mg and 20 mg are under way in the US and Europe to confirm these positive results.

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment.

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.

The active metabolite (2) of the novel immunosuppressive agent leflunomide (1) has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme catalyzes the fourth step in de

Novel Therapeutic Agents for the Treatment of Autoimmune Diseases

This review focuses on the evaluation of biological agents used in the treatment of Rheumatoid Arthritis, as well as potential antigen-Specific Therapies for multiple sclerosis.